Analysis of the antitumor activity of clotrimazole on A375 human melanoma cells

Anticancer Research

Volumn 35, Issue 7, 2015, Pages 3781-3786

  Adinolfi, Barbara ^b   Carpi, Sara ^a   Romanini, Antonella ^c   Da Pozzo, Eleonora ^a   Castagna, Maura ^a   Costa, Barbara ^a   Martini, Claudia ^a   Olesen, Søren Peter ^d   Schmitt, Nicole ^d   Breschi, Maria Cristina ^a   Nieri, Paola ^a   Fogli, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IFAC CNR   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

A375 cells; Apoptosis; Cell cycle; Clotrimazole; Hexokinase; Melanoma

Indexed keywords

CLOTRIMAZOLE; LIPOCORTIN 5; ANTINEOPLASTIC AGENT; CISPLATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DNA FRAGMENTATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; KERATINOCYTE; MELANOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; MELANOMA; METABOLISM; TUMOR CELL LINE;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CLOTRIMAZOLE; DNA FRAGMENTATION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; KERATINOCYTES; MELANOMA;

EID: 84937154361     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. 2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc Natl Acad Sci USA 95: 8280-8285, 1998.
2. Brugnara C, Gee B, Armsby CC, Kurth S, Sakamoto M, Rifai N, Alper SL, and Platt OS: Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 97: 1227-1234, 1996.
3. 1 and inhibits lung tumor cell growth in vitro and in vivo. J Pharmacol Exp Ther 308: 538-546, 2004.
4. Penso J and Beitner R: Clotrimazole decreases glycolysis and the viability of lung carcinoma and colon adenocarcinoma cells. Eur J Pharmacol 451: 227-235, 2002.
5. Gonçalves P, Gregório I, Araújo JR, and Martel F: The effect of clotrimazole on energy substrate uptake and carcinogenesis in intestinal epithelial cells. Anticancer Drugs 23: 220-229, 2012.
6. Furtado CM, Marcondes MC, Sola-Penna M, de Souza MLS, and Zancan P: Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLoS ONE 7: e30462, 2012.
7. Meira DD, Marinho-Carvalho MM, Teixeira CA, Veiga VF, Da Poian AT, Holandino C, de Freitas MS, and Sola-Penna M: Clotrimazole decreases human breast cancer cells viability through alterations in cytoskeleton-associated glycolytic enzymes. Mol Genet Metab 84: 354-362, 2005.
8. Mhawech-Fauceglia P, Kesterson J, Wang D, Akers S, Dupont NC, Clark K, Lele S, and Liu S: Expression and clinical significance of the transforming growth factor-β signalling pathway in endometrial cancer. Histopathology 59: 63-72, 2011.
9. Khalid MH, Tokunaga Y, Caputy AJ, and Walters E: Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. J Neurosurg 103: 79-86, 2005.
10. Hegemann L, Toso SM, Lahijani KI, Webster GF, and Uitto J: Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J Invest Dermatol 100: 343-346, 1993.
11. Wang J, Jia L, Kuang Z, Wu T, Hong Y, Chen X, Leung WK, Xia J, and Cheng B: The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma. PLoS ONE 9: e98885, 2014.
12. Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, and Wang YZ: Blockage of intermediate-conductance-Ca(2+)-activated K(+) channels inhibits progression of human endometrial cancer. Oncogene 26: 5107-5114, 2007.
13. Ito C, Tecchio C, Coustan-Smith E, Suzuki T, Behm FG, Raimondi SC, Pui C-H, and Campana D: The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis. Leukemia 16: 1344-1352, 2002.
14. 1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitro. Anticancer Drugs 21: 841-849, 2010.
15. Takei S, Iseda T, and Yokoyama M: Inhibitory effect of clotrimazole on angiogenesis associated with bladder epithelium proliferation in rats. Int J Urol 10: 78-85, 2003.
16. Coelho RG, Calaça I de C, Celestrini D de M, Correia AH, Costa MASM, and Sola-Penna M: Clotrimazole disrupts glycolysis in human breast cancer without affecting non-tumoral tissues. Mol Genet Metab 103: 394-398, 2011.
17. Marcondes MC, Sola-Penna M, and Zancan P: Clotrimazole potentiates the inhibitory effects of ATP on the key glycolytic enzyme 6-phosphofructo-1-kinase. Arch Biochem Biophys 497: 62-67, 2010.
18. Glass-Marmor L and Beitner R: Detachment of glycolytic enzymes from cytoskeleton of melanoma cells induced by calmodulin antagonists. Eur J Pharmacol 328: 241-248, 1997.
19. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, and Hay N: Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16: 819-830, 2004.
20. Rastrelli M, Tropea S, Rossi CR, and Alaibac M: Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo 28: 1005-1011, 2014.
21. Wolchok JD and Saenger YM: Current topics in melanoma. Curr Opin Oncol 19: 116-120, 2007.
22. Khalid MH, Shibata S, and Hiura T: Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. J Neurosurg 90: 918-927, 1999.
23. Zhang LJ, Hao YZ, Hu CS, Ye Y, Xie QP, Thorne RF, Hersey P, and Zhang XD: Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells. Anticancer Drugs 19: 159-166, 2008.
24. Pastorino JG and Hoek JB: Hexokinase II: the integration of energy metabolism and control of apoptosis. CMC 10: 1535-1551, 2003.
25. Pelicano H, Martin DS, Xu R-H, and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646, 2006.
26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
27. Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P, and Christensen C: Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 4: 584-599, 2013.
28. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, and Karagiannis TC: Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep 42: 841-851, 2015.